Assessment of minimal residual disease in a phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma Meeting Abstract
| Authors: | Landgren, O.; Alsina, M.; Biran, N.; Vesole, D. H.; Wallace, P. K.; Fang, B.; Arnold, G.; Kimball, A.; Siegel, D. S. |
| Abstract Title: | Assessment of minimal residual disease in a phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma |
| Meeting Title: | 62nd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 136 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2020 Dec 5-8 |
| Meeting Location: | Virtual |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2020-11-05 |
| Language: | English |
| ACCESSION: | WOS:000607547202247 |
| DOI: | 10.1182/blood-2020-133803 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 28 -- Source: Wos |
